Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
64,052.05 +1,613.39 (+2.58%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
ABT Jan 2025 75.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 03:52PM EDT
| Previous close | 0.6500 |
| Open | 0.5500 |
| Bid | 0.6000 |
| Ask | 0.6300 |
| Strike | 75.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.5500 - 0.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.04k |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.